Washington Post Publisher Will Lewis Steps Down After Layoffs 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Dublin, Nov. 27, 2017 -- The "Blood Disorders Pipeline Database - 2017 Update" report has been added to Research and Markets' offering.
Blood Disorders Pipeline Highlights Database - 2017 Update, provides most up-to-date information on key pipeline products in the global Blood Disorders Drug market. It covers emerging therapies for Blood Disorders in active clinical development stages including early and late stage clinical trials. Key indications covered in this database include Neutropenia, Sickle-cell Disorders, Thalassemia, Iron deficiency anemia, Haemophilia A, and Haemophilia B. The pipeline data is presented in an excel dashboard with filtering options.
The pipeline data presented in this database helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
By Indication:
The database presents pipeline by Blood Disorders indications. Key indications covered in this database include Neutropenia, Sickle-cell Disorders, Thalassemia, Iron deficiency anemia, Haemophilia A, and Haemophilia B.
By Clinical Trial Stages:
The database provides Blood Disorders pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
By Drug Mechanism Classes:
The database provides Blood Disorders pipeline products by their dominant drug mechanism class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
By Company:
The database provides Blood Disorders pipeline products by the company.
For more information about this report visit https://www.researchandmarkets.com/research/z22xpl/blood_disorders
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs
